PMC:7507645 / 15739-16437 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7507645","sourcedb":"PMC","sourceid":"7507645","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7507645","text":"Treatment with fremanezumab resulted in significantly greater reductions in the monthly average number of days of any acute headache medication use compared with placebo among patients with MO at baseline (LS mean difference [95% CI]: quarterly − 1.8 [− 2.9 to − 0.8], P = 0.0006; monthly − 2.4 [− 3.5 to − 1.4], P \u003c 0.0001; Fig. 1c) and patients without MO at baseline (quarterly − 1.6 [− 2.4 to − 0.9], monthly − 2.3 [− 3.1 to − 1.6]; P \u003c 0.0001 for both (Fig. 1c). Reductions from baseline in monthly average number of days with any acute headache medication use and treatment difference over placebo were numerically greater in fremanezumab-treated patients with MO than in patients without MO.","tracks":[]}